Compare AbbVie Inc (ABBV) vs Costco Wholesale Corporation (COST) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Costco (COST) trades at $961.80, up 1.22% with strong institutional buying interest. The stock shows bearish technical signals but maintains solid fundamentals with revenue growth to $275.24B in 2025 and consistent earnings beats. Recent March sales surged 11.3% year-over-year, demonstrating resilient consumer demand despite elevated valuation metrics including a P/E of 47.66. Analyst consensus remains strongly bullish with 65.5% buy ratings and a $1,110 price target.

The investment case hinges on Costco's membership-driven model and expansion potential, though high valuation presents near-term risk. Upside depends on sustained comp sales growth and margin expansion, while downside risks include consumer spending pressure and competitive threats. The stock trades 9.9% below its 52-week high, offering potential entry point for long-term investors comfortable with premium valuation.